2. Search Result
Search Result
Results for "

CRC

" in MedChemExpress (MCE) Product Catalog:

137

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

6

Peptides

5

Inhibitory Antibodies

16

Natural
Products

3

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139611
    Navlimetostat
    3 Publications Verification

    MRTX-1719; BMS-986504

    		 Histone Methyltransferase Cancer
    Navlimetostat is a potent, orally active, selective PRMT5-MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5-MTA and PRMT5. Navlimetostat binds to the PRMT5-MTA complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .
    Navlimetostat
  • HY-B0008
    Sulindac

    MK-231

    		 NF-κB PD-1/PD-L1 Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac
  • HY-N2146
    Combretastatin A4
    4 Publications Verification

    CRC 87-09

    		 Microtubule/Tubulin Cancer
    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
    Combretastatin A4
  • HY-135103
    Tauro-β-muricholic acid sodium
    4 Publications Verification

    T-βMCA sodium

    		 FXR Cancer
    Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM .
    Tauro-β-muricholic acid sodium
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-169422
    GSK4418959

    IDE275

    		 DNA/RNA Synthesis Cancer
    GSK4418959 (IDE275) is a selective, reversible and orally active WRN helicase inhibitor. GSK4418959 shows >10,000-fold selectivity over other helicases. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer, such as colorectal cancer (CRC) and endometrial cancer (EC) .
    GSK4418959
  • HY-B0294
    Flubendazole
    Maximum Cited Publications
    8 Publications Verification

    		 Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole
  • HY-N2187
    Deoxyshikonin
    3 Publications Verification

    		 Bacterial HIF/HIF Prolyl-Hydroxylase PI3K Apoptosis Infection Cardiovascular Disease Cancer
    Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
    Deoxyshikonin
  • HY-145120
    Mosperafenib

    RG6344; RO7276389; B-Raf IN 2

    		 Raf Cancer
    BRAF inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC) .
    Mosperafenib
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Inflammation/Immunology Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-156112
    LM2I

    		Ser/Thr Protease Cancer
    LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .
    LM2I
  • HY-114491
    Rineterkib

    		ERK Raf Cancer
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib
  • HY-B1414
    Chloroxylenol
    3 Publications Verification

    p-Chloro-m-xylenol; PCMX

    		 Environmental Pollutants Bacterial Parasite Influenza Virus Infection
    Chloroxylenol is a broad-spectrum antibacterial agent that can be used to control bacteria, algae, fungi and viruses .
    Chloroxylenol
  • HY-120675
    SSTC3
    2 Publications Verification

    		 Casein Kinase Wnt Cancer
    SSTC3 is a casein kinase 1α (CK1α) activator (Kd = 32 nM) that inhibits WNT signaling (EC50 = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors .
    SSTC3
  • HY-120852
    JG26
    1 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) MMP EGFR ERK SARS-CoV Infection Cardiovascular Disease Cancer
    JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases .
    JG26
  • HY-107460
    LDN-211904 oxalate
    1 Publications Verification

    		 Ephrin Receptor Cancer
    LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
    LDN-211904 oxalate
  • HY-139065
    AMPC

    		Apoptosis Cancer
    AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .
    AMPC
  • HY-148660
    SFI003

    		Apoptosis Reactive Oxygen Species (ROS) Cancer
    SFI003 is a SRSF3 inhibitor that drives CRC cell apoptosis via the SRSF3/DHCR24/ROS axis and exhibits potent antitumor effects both in vitro and in vivo .
    SFI003
  • HY-P1201
    Cyclosomatostatin
    1 Publications Verification

    		 Somatostatin Receptor Cancer
    Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
    Cyclosomatostatin
  • HY-151629
    MRV03-069

    		Bacterial Cancer
    MRV03-069 (Compound 3) is a selective colibactin-activated peptidase (ClbP) inhibitor that blocks the genotoxic effect of Colibactin (HY-145930) on eukaryotic cells. MRV03-069 can be used in colorectal cancer research .
    MRV03-069
  • HY-114977
    Avenanthramide A

    		DNA/RNA Synthesis Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a KD of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis .
    Avenanthramide A
  • HY-123772
    CDK5 inhibitor 20-223
    1 Publications Verification

    CP668863

    		 CDK Cancer
    CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .
    CDK5 inhibitor 20-223
  • HY-108695
    Enterodiol

    		Apoptosis Endogenous Metabolite Cancer
    Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .
    Enterodiol
  • HY-122347A
    Orvepitant maleate

    GW823296 maleate

    		 Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Orvepitant maleate (GW823296 maleate) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pKi of 10.2 for human neurokinin-1 receptor. Orvepitant maleate can across the blood-brain barrier. Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatment .
    Orvepitant maleate
  • HY-175783
    MM927

    		Apoptosis Cancer
    MM927 is a potent NVL inhibitor, with an IC50 of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC) .
    MM927
  • HY-153833
    PDS-0330
    1 Publications Verification

    KVA-E-23A

    		 Gap Junction Protein Cancer
    PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .
    PDS-0330
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    		 Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-109963
    PR5-LL-CM01

    		Histone Methyltransferase Cancer
    PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies .
    PR5-LL-CM01
  • HY-155554
    SCAL-255

    		Mitochondrial Metabolism Oxidative Phosphorylation Reactive Oxygen Species (ROS) MMP Cancer
    SCAL-255 is a potent mitochondrial complex I (CI) inhibitor with an IC50 of 1.14 μM. SCAL-255 blocks mitochondrial function, inhibits oxygen consumption rate (OCR), induces reactive oxygen species (ROS) production, and reduces MMP. SCAL-255 can be used in the research of oxidative phosphorylation (OXPHOS)-dependent cancers, such as colorectal cancer (CRC) and acute myeloid leukemia (AML), etc .
    SCAL-255
  • HY-P6083
    RTSPSSR

    		Biochemical Assay Reagents Others Cancer
    RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .
    RTSPSSR
  • HY-163828
    PPA24

    		Apoptosis Phosphatase c-Myc GSK-3 ERK Reactive Oxygen Species (ROS) Cancer
    PPA24 is a PP2A activator with a KD of 8.465 μM for PP2ACα. PPA24 induces cancer cell death via apoptosis. PP2ACα induces ROS generation and decreases the level of c-Myc expression. PPA24 can be used to study colorectal cancer (CRC), Folinic acid (HY-17556), 5-Fluorouracil (HY-90006), and Oxaliplatin (HY-17371) (FOLFOX)-resistant CRC, and melanoma cancer .
    PPA24
  • HY-N3001
    Isolinderalactone
    1 Publications Verification

    		 STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase Neurological Disease Inflammation/Immunology Cancer
    Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
    Isolinderalactone
  • HY-172807
    p38α-IN-9

    		p38 MAPK MAPKAPK2 (MK2) CDK Wee1 Cancer
    p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2 T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .
    p38α-IN-9
  • HY-Y0106
    2,6-Dihydroxyacetophenone

    		mTOR Xanthine Oxidase Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .
    2,6-Dihydroxyacetophenone
  • HY-139611B
    (S)-Navlimetostat

    (S)-MRTX-1719; (S)-BMS-986504

    		 Histone Methyltransferase Cancer
    (S)-Navlimetostat (example 16-7) is the S-enantiomer of Navlimetostat. (S)-Navlimetostat is a PRMT5/MTA complex inhibitor, with an IC50 of 7070 nM .
    (S)-Navlimetostat
  • HY-175753
    Z17544625

    		Others Cancer
    Z17544625 is a Fascin inhibitor. Z17544625 has a strong binding capacity to fascin and inhibits Actin bundling. Z17544625 significantly reduces proliferation and impairs migration of CRC cells. Z17544625 can be used for cancer, especially colorectal cancer (CRC) research .
    Z17544625
  • HY-155068
    FC-116

    		Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis PERK Eukaryotic Initiation Factor (eIF) IRE1 Cancer
    FC-11 is a tubulin inhibitor. FC-116 inhibits the proliferation of colorectal cancer (CRC) cells, with IC50 values of 4.52 nM for HCT116 cells and 18.69 nM for CT26 cells. FC-11 can induce ER stress to generate excess ROS, leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-116 exerts potent anti-tumor effects in vivo. FC-11 can be used for the study of colorectal cancer .
    FC-116
  • HY-108695B
    (±)-Enterodiol

    		Apoptosis Endogenous Metabolite Cancer
    (±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .
    (±)-Enterodiol
  • HY-B0294R
    Flubendazole (Standard)

    		Reference Standards Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole (Standard)
  • HY-151939
    BLM-IN-2

    		DNA/RNA Synthesis Apoptosis Cancer
    BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC50 value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .
    BLM-IN-2
  • HY-113264
    PGD2 ethanolamide

    		Apoptosis Cancer
    PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .
    PGD2 ethanolamide
  • HY-N3913
    Furowanin A

    		STAT Bcl-2 Family Cancer
    Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .
    Furowanin A
  • HY-155391
    hCA/Wnt/β-catenin-IN-1

    		Carbonic Anhydrase P-glycoprotein Wnt β-catenin Cancer
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .
    hCA/Wnt/β-catenin-IN-1
  • HY-P991635
    PF-07329640

    		TNF Receptor Cancer
    PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
    PF-07329640
  • HY-116572
    TASIN-1 hydrochloride

    		Reactive Oxygen Species (ROS) JNK Apoptosis Caspase Cancer
    TASIN-1 hydrochloride is a selective inhibitor of truncated APC TR (adenomatous polyposis coli gene) that exerts cytotoxic effects by inhibiting cholesterol biosynthesis. TASIN-1 hydrochloride specifically targets colorectal cancer (CRC) cells carrying APC truncated mutations, while having no significant toxicity to wild-type APC cells. TASIN-1 hydrochloride exerts cytotoxic effects by targeting Emopamil binding protein (EBP) to inhibit cholesterol biosynthesis, triggering endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) generation, and JNK-mediated apoptosis, and inhibiting Akt survival signaling. TASIN-1 hydrochloride can be used to prevent and intervene in APC mutant colorectal cancer .
    TASIN-1 hydrochloride
  • HY-108433
    CPT2

    Carnitine palmitoyltransferase 2

    		 Apoptosis MDM-2/p53 Metabolic Disease Cancer
    CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
    CPT2
  • HY-154973
    AMPK activator 11

    		Oxidative Phosphorylation Mitochondrial Metabolism AMPK Metabolic Disease Cancer
    AMPK activator 11 is an AMP-activated protein kinase (AMPK) activator with nanomolelevel antiproliferation activities against several CRCs. AMPK activator 11 selectively inhibits the RKO xenograft growth along by activating AMPK and upregulating oxidative phosphorylation (OXPHOS) ( mitochondrial metabolism ) and can be used for anti-tumor and metabolic disease research .
    AMPK activator 11
  • HY-175558
    MMP-9-IN-12

    		MMP Apoptosis Reactive Oxygen Species (ROS) Cancer
    MMP-9-IN-12 is a matrix metalloproteinase-9 (MMP-9) inhibitor with an IC50 of 6.57 μM. MMP-9-IN-12 shows an IC50 value of 1.54 μM for HCT-116 cells. MMP-9-IN-12 induces cell apoptosis, ROS production and mitochondrial depolarization. MMP-9-IN-12 inhibits cells migration and disrupts cell cycle progression. MMP-9-IN-12 can be used for the research of colorectal cancer (CRC) .
    MMP-9-IN-12
  • HY-N2146R
    Combretastatin A4 (Standard)

    CRC 87-09 (Standard)

    		 Reference Standards Microtubule/Tubulin Cancer
    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
    Combretastatin A4 (Standard)
  • HY-136358
    LDN-211904

    		Ephrin Receptor Cancer
    LDN-211904 is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .
    LDN-211904

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: